Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
immunology and microbiology
Suppression of Immunopathology in Schistosomiasis by Interleukin-2-Targeted Fusion Toxin, DAB
389
IL-2 I. Studies ofin Vitroandin VivoEfficacy
Cellular Immunology, Volume 166, No. 2, Year 1995
Notification
URL copied to clipboard!
Description
Schistosomiasis causes pathology in an estimated 200 million individuals. Clinical disease is caused by a complex immunopathologic response to the parasite ova, which are deposited in the host tissues. This immunopathologic response is caused by T lymphocytes which express the high-affinity IL-2 receptor (IL-2R). DAB389IL-2 is a diphtheria toxin-IL-2 fusion toxin protein which functionally inactivates or kills cells which bear the high-affinity IL-2R. DAB389IL-2 has been used in man to suppress IL-2R-dependent immune reactivity. Therefore, we reasoned that DAB389IL-2 might suppress immunopathology in schistosomiasis. In these studies we assessed thein vitroandin vivoeffects of DAB389IL-2 on the development of immunopathology in murine schistosomiasis. DAB389IL-2 suppressed IL-2, lectin mitogen (Con A), and solubleSchistosoma mansoniegg antigen-induced lymphocyte proliferation andin vitrogranuloma formation. In addition, DAB389IL-2 suppressedin vitroIL-2R expression. DAB389IL-2 also suppressed the development of granulomas and collagen depositionin vivoin the livers of infected animals. Therefore, DAB389IL-2 may have potential for the targeted reduction of immunopathology due to schistosomiasis in man. © 1995.
Authors & Co-Authors
Ramadan, Mohamed Anwar
United States, Philadelphia
University of Pennsylvania
Gabr, Nabil Shokrany
Egypt, Minya
Faculty of Medicine
Bacha, Patricia
United States, Hopkinton
Seragen, Inc.
Günzler, Volkmar
France, Gentilly
Sanofi S.a.
Phillips, S. Michael
United States, Philadelphia
University of Pennsylvania
Statistics
Citations: 12
Authors: 5
Affiliations: 4
Identifiers
Doi:
10.1006/cimm.1995.9976
ISSN:
00088749
e-ISSN:
10902163
Research Areas
Infectious Diseases